Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series

Kevin Drenner; Gargi D. Basu; Laurie J. Goodman; Audrey A. Ozols; Janine R. LoBello; Thomas Royce; Michael S. Gordon; Erkut H. Borazanci; Margaux A. Steinbach; Jeffrey Trent; Sunil Sharma

doi:10.18632/oncotarget.28294

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series

PDF | How to cite

Oncotarget. 2022; 13:1174-1174. https://doi.org/10.18632/oncotarget.28294

Metrics: PDF 660 views | ?

Kevin Drenner^1,*, Gargi D. Basu^2,*, Laurie J. Goodman², Audrey A. Ozols², Janine R. LoBello², Thomas Royce², Michael S. Gordon³, Erkut H. Borazanci³, Margaux A. Steinbach³, Jeffrey Trent¹ and Sunil Sharma¹

¹Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA
²Ashion Analytics, LLC, Phoenix, AZ 85004, USA
³HonorHealth Research Institute, Scottsdale, AZ 85258, USA
^*These authors contributed equally to this work

Published: October 20, 2022

Copyright: © 2022 Drenner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The study, protocol # HRI-0029 is an IRB approved clinical study, WIRB # 20182804, and all patients signed informed consent to participate.

Original article: Oncotarget. 2021; 12:1836–1847. DOI: https://doi.org/10.18632/oncotarget.28046

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28294

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series